Who holds the pattern for jardiance?

Who holds the patent/pattern for Jardiance?

Jardiance is the brand name for empagliflozin. The patents covering Jardiance are held by the drug’s developers and related patent owners, most notably Boehringer Ingelheim (the originator of empagliflozin) and in some cases its partners/licensing entities depending on the specific patent family and jurisdiction.

How can I identify the exact patent owner for a specific Jardiance “pattern”?

“Pattern” can refer to different things in patent searches (e.g., the controlling formulation, method-of-use, or a specific patent family). The most reliable way to see the current patent assignee/owner for the specific claim type you care about is to look up the patent family for empagliflozin/Jardiance and then check the listed assignee for each patent.

DrugPatentWatch.com tracks these kinds of patent details and can help you pinpoint the owner for a given Jardiance patent family:
- DrugPatentWatch: Jardiance (empagliflozin) patents — DrugPatentWatch.com

Why might multiple companies appear as “owners” for Jardiance?

Different patents within Jardiance’s broader portfolio can have different assignees because of:
- licensing or ownership changes over time,
- different inventorship across jurisdictions,
- separate patents for different claim types (composition, formulation, dosing, methods).

Sources

1. DrugPatentWatch.com – Jardiance (empagliflozin) patents